Frank C. Kuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Frank C. Kuo has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Janina A. Longtine
3 shared publicationsDimity Hall
Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, Massachusetts
2 shared publications- Priyanka Shivdasani
Department of Pathology and
2 shared publications Aaron R. Thorner
Center for Cancer Genome Discovery, DFCI, Boston, Massachusetts, USA
1 shared publication- Adrian M. Dubuc
Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
1 shared publication - Alanna Church
Department of Pathology, Boston Children's Hospital, Boston, Massachusetts, USA
1 shared publication
Latest Publications
- 1 January 2019
- Published by Elsevier in Seminars in Hematology
- Vol. 56 (1) , 2-6
Next generation sequencing in hematolymphoid neoplasia
- 1 January 2019
- Published by Elsevier in Seminars in Hematology
- Vol. 56 (1) , 2-6
Next generation sequencing in hematolymphoid neoplasia
- Open Access
- 22 February 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (4)
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
Programmed cell death protein 1 (PD-1) inhibitors have efficacy in treating squamous cell carcinoma of the head and neck (SCCHN), but objective response rates are low. PD-1 ligand (PD-L1) expression alone is not considered a robust predictor of response and additional biomarkers are needed. This 3-year observational cohort followed 126 SCCHN patients treated with anti–PD-1/L1 therapy. Prior to treatment, 81 (64%) had targeted massively parallel tumor sequencing. Of these, 42 (52%) underwent fluorescence-activated cell sorting and PD-L1 immunohistochemistry for tumor immunoprofiling. Six (5%) complete responses (CRs) and 11 (9%) partial responses (PRs) were observed. Those treated with prior chemotherapy (98, 78%) versus only surgery and/or radiation had longer overall survival (OS) (10 vs. 3 months, P = 0.02). Smokers had a higher total mutational burden (TMB) ( P = 0.01). Virus-positive patients had a lower TMB ( P < 0.01) and improved OS ( P = 0.02). Among virus-negative responders, NOTCH1 and SMARCA4 were more frequently mutated and frameshift events in tumor suppressor genes occurred more frequently ( P = 0.03). Higher TMB and CD8 + T cell infiltrates predicted anti–PD-1/L1 benefit ( P < 0.01, P < 0.01, respectively) among virus-negative tumors. TIM-3/LAG-3 coexpression with PD-1 was higher on T cells among nonresponders ( P = 0.03 and 0.02, respectively). Somatic frameshift events in tumor suppressor genes and higher TMB among virus-negative SCCHN tumors predict anti–PD-1/L1 response.
- 22 February 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (4)
Open AccessFrameshift events predict anti–PD-1/L1 response in head and neck cancer
Programmed cell death protein 1 (PD-1) inhibitors have efficacy in treating squamous cell carcinoma of the head and neck (SCCHN), but objective response rates are low. PD-1 ligand (PD-L1) expression alone is not considered a robust predictor of response and additional biomarkers are needed. This 3-year observational cohort followed 126 SCCHN patients treated with anti–PD-1/L1 therapy. Prior to treatment, 81 (64%) had targeted massively parallel tumor sequencing. Of these, 42 (52%) underwent fluorescence-activated cell sorting and PD-L1 immunohistochemistry for tumor immunoprofiling. Six (5%) complete responses (CRs) and 11 (9%) partial responses (PRs) were observed. Those treated with prior chemotherapy (98, 78%) versus only surgery and/or radiation had longer overall survival (OS) (10 vs. 3 months, P = 0.02). Smokers had a higher total mutational burden (TMB) ( P = 0.01). Virus-positive patients had a lower TMB ( P < 0.01) and improved OS ( P = 0.02). Among virus-negative responders, NOTCH1 and SMARCA4 were more frequently mutated and frameshift events in tumor suppressor genes occurred more frequently ( P = 0.03). Higher TMB and CD8 + T cell infiltrates predicted anti–PD-1/L1 benefit ( P < 0.01, P < 0.01, respectively) among virus-negative tumors. TIM-3/LAG-3 coexpression with PD-1 was higher on T cells among nonresponders ( P = 0.03 and 0.02, respectively). Somatic frameshift events in tumor suppressor genes and higher TMB among virus-negative SCCHN tumors predict anti–PD-1/L1 response.
- Top Cited PapersOpen Access
- 17 November 2016
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 1 (19) , e87062
Institutional implementation of clinical tumor profiling on an unselected cancer population
BACKGROUND. Comprehensive genomic profiling of a patient’s cancer can be used to diagnose, monitor, and recommend treatment. Clinical implementation of tumor profiling in an enterprise-wide, unselected cancer patient population has yet to be reported. METHODS. We deployed a hybrid-capture and massively parallel sequencing assay (OncoPanel) for all adult and pediatric patients at our combined cancer centers. Results were categorized by pathologists based on actionability. We report the results for the first 3,727 patients tested. RESULTS. Our cohort consists of cancer patients unrestricted by disease site or stage. Across all consented patients, half had sufficient and available (>20% tumor) material for profiling; once specimens were received in the laboratory for pathology review, 73% were scored as adequate for genomic testing. When sufficient DNA was obtained, OncoPanel yielded a result in 96% of cases. 73% of patients harbored an actionable or informative alteration; only 19% of these represented a current standard of care for therapeutic stratification. The findings recapitulate those of previous studies of common cancers but also identify alterations, including in AXL and EGFR , associated with response to targeted therapies. In rare cancers, potentially actionable alterations suggest the utility of a “cancer-agnostic” approach in genomic profiling. Retrospective analyses uncovered contextual genomic features that may inform therapeutic response and examples where diagnoses revised by genomic profiling markedly changed clinical management. CONCLUSIONS. Broad sequencing-based testing deployed across an unselected cancer cohort is feasible. Genomic results may alter management in diverse scenarios; however, additional barriers must be overcome to enable precision cancer medicine on a large scale. FUNDING. This work was supported by DFCI, BWH, and the National Cancer Institute (5R33CA155554 and 5K23CA157631).
- 17 November 2016
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 1 (19) , e87062
Top Cited PapersOpen AccessInstitutional implementation of clinical tumor profiling on an unselected cancer population
BACKGROUND. Comprehensive genomic profiling of a patient’s cancer can be used to diagnose, monitor, and recommend treatment. Clinical implementation of tumor profiling in an enterprise-wide, unselected cancer patient population has yet to be reported. METHODS. We deployed a hybrid-capture and massively parallel sequencing assay (OncoPanel) for all adult and pediatric patients at our combined cancer centers. Results were categorized by pathologists based on actionability. We report the results for the first 3,727 patients tested. RESULTS. Our cohort consists of cancer patients unrestricted by disease site or stage. Across all consented patients, half had sufficient and available (>20% tumor) material for profiling; once specimens were received in the laboratory for pathology review, 73% were scored as adequate for genomic testing. When sufficient DNA was obtained, OncoPanel yielded a result in 96% of cases. 73% of patients harbored an actionable or informative alteration; only 19% of these represented a current standard of care for therapeutic stratification. The findings recapitulate those of previous studies of common cancers but also identify alterations, including in AXL and EGFR , associated with response to targeted therapies. In rare cancers, potentially actionable alterations suggest the utility of a “cancer-agnostic” approach in genomic profiling. Retrospective analyses uncovered contextual genomic features that may inform therapeutic response and examples where diagnoses revised by genomic profiling markedly changed clinical management. CONCLUSIONS. Broad sequencing-based testing deployed across an unselected cancer cohort is feasible. Genomic results may alter management in diverse scenarios; however, additional barriers must be overcome to enable precision cancer medicine on a large scale. FUNDING. This work was supported by DFCI, BWH, and the National Cancer Institute (5R33CA155554 and 5K23CA157631).
- 1 September 2016
- Published by Elsevier in Surgical Pathology Clinics
- Vol. 9 (3) , 475-488
Molecular Pathology
- 1 September 2016
- Published by Elsevier in Surgical Pathology Clinics
- Vol. 9 (3) , 475-488
Molecular Pathology
- 1 July 2016
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 18 (4) , 507-515
Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies
- 1 July 2016
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 18 (4) , 507-515
Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies
- 2 May 2015
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 10 (2) , 104-111
Next-Generation Sequencing-Based Panel Testing for Myeloid Neoplasms
Our ability to interrogate a broad array of genetic alterations in myeloid neoplasm has increased significantly with the advance in next-generation sequencing (NGS). In addition to morphologic examination, flow cytometry, and cytogenetics, NGS-based testing can add additional information to the diagnostic workup. More than a dozen myeloid-focused NGS-based panels are now available from commercial and academic laboratories. In this review, we examine the content of these panels in the context of our current understanding of driver alterations in myeloid neoplasms. With improved turnaround time, decreasing costs, and an expanding knowledge of the therapeutic and prognostic significance of the detected variants, NGS-based panel testing is likely to play a major role in the management of patients with myeloid neoplasm in the coming decade.
- 2 May 2015
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 10 (2) , 104-111
Next-Generation Sequencing-Based Panel Testing for Myeloid Neoplasms
Our ability to interrogate a broad array of genetic alterations in myeloid neoplasm has increased significantly with the advance in next-generation sequencing (NGS). In addition to morphologic examination, flow cytometry, and cytogenetics, NGS-based testing can add additional information to the diagnostic workup. More than a dozen myeloid-focused NGS-based panels are now available from commercial and academic laboratories. In this review, we examine the content of these panels in the context of our current understanding of driver alterations in myeloid neoplasms. With improved turnaround time, decreasing costs, and an expanding knowledge of the therapeutic and prognostic significance of the detected variants, NGS-based panel testing is likely to play a major role in the management of patients with myeloid neoplasm in the coming decade.
- 30 September 2011
- Published by Elsevier in Leukemia Research
- Vol. 35 (9) , 1188-1192
Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation
- 30 September 2011
- Published by Elsevier in Leukemia Research
- Vol. 35 (9) , 1188-1192
Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation
- Open Access
- 8 February 2011
- Published by Wiley in American Journal of Hematology
- Vol. 86 (4) , 384
Response to Helsby and Tingle
- 8 February 2011
- Published by Wiley in American Journal of Hematology
- Vol. 86 (4) , 384
Open AccessResponse to Helsby and Tingle
- 1 February 2007
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 9 (1) , 12-19
A Novel Method for Interpretation of T-Cell Receptor γ Gene Rearrangement Assay by Capillary Gel Electrophoresis Based on Normal Distribution
- 1 February 2007
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 9 (1) , 12-19
A Novel Method for Interpretation of T-Cell Receptor γ Gene Rearrangement Assay by Capillary Gel Electrophoresis Based on Normal Distribution
- Open Access
- 6 March 2006
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 6 (1) , 12
Development and evaluation of an open source software tool for deidentification of pathology reports
Background: Electronic medical records, including pathology reports, are often used for research purposes. Currently, there are few programs freely available to remove identifiers while leaving the remainder of the pathology report text intact. Our goal was to produce an open source, Health Insurance Portability and Accountability Act (HIPAA) compliant, deidentification tool tailored for pathology reports. We designed a three-step process for removing potential identifiers. The first step is to look for identifiers known to be associated with the patient, such as name, medical record number, pathology accession number, etc. Next, a series of pattern matches look for predictable patterns likely to represent identifying data; such as dates, accession numbers and addresses as well as patient, institution and physician names. Finally, individual words are compared with a database of proper names and geographic locations. Pathology reports from three institutions were used to design and test the algorithms. The software was improved iteratively on training sets until it exhibited good performance. 1800 new pathology reports were then processed. Each report was reviewed manually before and after deidentification to catalog all identifiers and note those that were not removed. Results: 1254 (69.7 %) of 1800 pathology reports contained identifiers in the body of the report. 3439 (98.3%) of 3499 unique identifiers in the test set were removed. Only 19 HIPAA-specified identifiers (mainly consult accession numbers and misspelled names) were missed. Of 41 non-HIPAA identifiers missed, the majority were partial institutional addresses and ages. Outside consultation case reports typically contain numerous identifiers and were the most challenging to deidentify comprehensively. There was variation in performance among reports from the three institutions, highlighting the need for site-specific customization, which is easily accomplished with our tool. Conclusion: We have demonstrated that it is possible to create an open-source deidentification program which performs well on free-text pathology reports.
- 6 March 2006
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 6 (1) , 12
Open AccessDevelopment and evaluation of an open source software tool for deidentification of pathology reports
Background: Electronic medical records, including pathology reports, are often used for research purposes. Currently, there are few programs freely available to remove identifiers while leaving the remainder of the pathology report text intact. Our goal was to produce an open source, Health Insurance Portability and Accountability Act (HIPAA) compliant, deidentification tool tailored for pathology reports. We designed a three-step process for removing potential identifiers. The first step is to look for identifiers known to be associated with the patient, such as name, medical record number, pathology accession number, etc. Next, a series of pattern matches look for predictable patterns likely to represent identifying data; such as dates, accession numbers and addresses as well as patient, institution and physician names. Finally, individual words are compared with a database of proper names and geographic locations. Pathology reports from three institutions were used to design and test the algorithms. The software was improved iteratively on training sets until it exhibited good performance. 1800 new pathology reports were then processed. Each report was reviewed manually before and after deidentification to catalog all identifiers and note those that were not removed. Results: 1254 (69.7 %) of 1800 pathology reports contained identifiers in the body of the report. 3439 (98.3%) of 3499 unique identifiers in the test set were removed. Only 19 HIPAA-specified identifiers (mainly consult accession numbers and misspelled names) were missed. Of 41 non-HIPAA identifiers missed, the majority were partial institutional addresses and ages. Outside consultation case reports typically contain numerous identifiers and were the most challenging to deidentify comprehensively. There was variation in performance among reports from the three institutions, highlighting the need for site-specific customization, which is easily accomplished with our tool. Conclusion: We have demonstrated that it is possible to create an open-source deidentification program which performs well on free-text pathology reports.